Navigation Links
First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
Date:5/29/2008

T) and then Herceptin(R) monotherapy (6 mg/kg every

three weeks) to complete one year of Herceptin(R) treatment

- TCH (n=1.075), the non-anthracycline experimental regimen consisting of

Taxotere(R) (T, 75 mg/m2) plus carboplatin (C; AUC 6 mg/mL/min) every

three weeks for six cycles plus Herceptin(R) (H, 4 mg/kg loading dose

followed by 2 mg/kg per week concurrently with TC) and then Herceptin(R)

monotherapy (6 mg/kg every three weeks) to complete one year of

Herceptin(R) treatment.

The primary endpoint of the study was to compare disease-free survival (DFS) of each of the experimental regimens (TCH or AC-TH) with standard anthracycline-based chemotherapy (AC-T).

Secondary endpoints included evaluation of overall survival (OS) and cardiac toxicity. The first analysis (considered as the primary) was presented at the SABCS in 2006 and the updated results were communicated at SABCS in 2007.

Efficacy results

DFS was significantly improved by one third (33 percent) in the TCH treatment arm (HR=0.67, 95% CI [0.54-0.83], p=0.0003) and 39 percent (HR=0.61, 95% CI [0.49-0.77], p<0.0001) in the AC-TH arm, compared to the AC-T control arm. The DFS benefit of TCH and AC-TH was present regardless of a patient's age, the tumor responsiveness to hormones (hormone receptor status), or whether or not the cancer had spread to lymph nodes (nodal status). There was no statistically significant difference in DFS between the two experimental arms (TCH and AC-TH).

OS was also significantly improved with the TCH regimen with 34% reduction in the risk of death (HR=0.66, 95% CI [0.47-0.93], p=0.0182) compared to the AC-T control arm. Similarly, AC-TH was associated with a 42% reduction in the risk of death (HR=0.58, 95% CI [0.40-0.83], p=0.0024) compared to the AC-T control arm. There was no statistically significant difference in OS between the two experimental arms (TCH and AC-TH).

Tolerance '/>"/>

SOURCE Cancer International Research Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... the forefront of diagnostics today, with imaging techniques ... scanning, and NMR (nuclear magnetic resonance) increasing steeply ... of image resolution and quality still limit these ... A solution is hyperpolarization, which involves injecting the ... by following the distribution and fate of specific ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
(Date:9/29/2014)... 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that its three Promissory Note holders, two of ... 100,000 each in July 2014 for a total of ... Coupons converted into 3,500,001 restricted common shares. Notes were ... the Note and the coupon were convertible into common ...
(Date:9/29/2014)... batteries are efficient but involve a range of ... (lucerne seed) and pine resin and a clever ... with a highly interesting alternative. Their study will ... ChemSusChem . , ,We think our discovery can ... for the batteries of the future, says Daniel ...
Breaking Biology Technology:A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Smart, eco-friendly new battery to solve problems 2
... Nov. 17 Doctors Research Group, Inc. announced today ... Food and Drug Administration (FDA) to market KRYPTONITE(TM) Bone ... a major advancement in treating cranial defects due to ... exotherm cement and bone void filler approved for cranioplasty ...
... , SAN FRANCISCO, Nov. 17 Merriman Curhan Ford Group, ... in PolyMedix Inc.,s (OTC Bulletin Board: PYMX) $20.7 million registered ... priced at $1.00 per unit, consist of one share of ... 0.30 of a share of PolyMedix common stock at $1.25 ...
... TSX symbol: SBS , CALGARY, Nov. 17 /PRNewswire-FirstCall/ - ... Court of Queen,s Bench of Alberta has issued an ... of the securityholders of SemBioSys, at which securityholders will ... (the "Arrangement") involving the corporate reorganization with Cathedral Energy ...
Cached Biology Technology:Doctors Research Group Receives FDA Clearance for U.S. Distribution of KRYPTONITE(TM) Bone Cement 2Merriman Curhan Ford Acted as Lead Placement Agent in PolyMedix's $20.7 Million Equity Financing 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 2SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009 3
(Date:9/30/2014)... strawberries all have in common? Unlike most eukaryotic ... are diploid, these organisms are all polyploid, meaning they ... salmon have 3 and 4 sets of chromosomes, respectively, ... surprising, in fact most plant species are polyploid. Polyploidy, ... ago, but only recently, with the development of molecular ...
(Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 2Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 3Gene doubling shapes the world: Instant speciation, biodiversity, and the root of our existence 4Contaminated water linked to pregnancy complications, BU study finds 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... structure mapping and thermodynamics is introduced for RNA pseudoknot ... the context of the biological folding direction (5 to ... information about the flexibility of the RNA. Mapping methods ... and add important 3D structural considerations. The model suggests ...
... National Institute of Allergy and Infectious Diseases (NIAID) of the ... Mary Woodard Lasker Award for Public Service for his role ... and biodefense. The award will be presented on Friday, September ... Dr. Fauci is honored for his role in helping develop ...
... America (ESA), in cooperation with the American Phytopathological ... Small Grain Insects, the latest in ESAs Insect ... the biology and management of arthropod pests and ... with expertise on specific pest groups have provided ...
Cached Biology News:Anthony S. Fauci awarded Lasker Award for Public Service 2Anthony S. Fauci awarded Lasker Award for Public Service 3Anthony S. Fauci awarded Lasker Award for Public Service 4Handbook of small grain insects available now 2
... ATPase α-1, clone C464.6 GenBank Accession ... Na + /K + ATPase isolated ... medulla Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... routinely evaluated in immunoblot on rat brain ...
PSGL-1 (215)...
Mouse monoclonal [1-N-14] to Adenovirus Type 7 hexon C11 Immunogen: Purified Adenovirus type 7 Specificity: This antibody is specific for Adenovirus type 7 hexon C11....
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Biology Products: